- Industry: Government; Health care
- Number of terms: 6957
- Number of blossaries: 0
- Company Profile:
The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH), which is one of 11 agencies that compose the Department of Health and Human Services (HHS). The NCI, established under the National Cancer Institute Act of 1937, is the Federal Government's principal agency for ...
A cancer vaccine containing four HLA-A*0201-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Vaccine peptide epitopes are derived from the tumor associated antigens (TAAs) tyrosinase-related protein 2 (TRP2), glycoprotein 100 (gp100), Ephrin receptor A2 (EphA2) and human epidermal growth factor receptor 2 (HER2). Upon administration, HLA-A*0201-restricted TRp2-gp100-EphA2-HER2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against TRP2-gp100-EphA2-HER2-expressing tumor cells, resulting in tumor cell lysis and decreased tumor cell proliferation. HLA-A*0201 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*0201 may improve antigenic peptide immunogenicity.
Industry:Pharmaceutical
A cancer vaccine containing five peptide epitopes with potential immunostimulatory and antitumor activity. Peptide epitopes in this vaccine are derived from: URLC10 (up-regulated lung cancer 10), TTK (TTK protein kinase), KOC1 (IGF II mRNA Binding Protein 3) and VEGFRs (vascular endothelial growth factor receptors) 1 and 2. Upon administration, URLC10-TTK-KOC1-VEGFR1-VEGFR2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing URLC10, TTK, KCO1, VEGFR 1 and 2 peptides, resulting in cell lysis and decreased tumor growth.
Industry:Pharmaceutical
A cancer vaccine containing five HLA-A*2402-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from IGF II mRNA binding protein 3 (KOC1); TTK protein kinase (TTK); URLC10 (up-regulated lung cancer 10); DEP domain containing 1 (DEPDC1); and M phase phosphoprotein 1 (MPHOSPH1). Upon administration, HLA-A*2404-restricted KOC1-TTK-CO16-DEPDC1-MPHOSPH1 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing KOC1, TTK, CO16, DEPDC1 and MPHOSPH1 peptides, resulting in tumor cell lysis and decreased tumor growth. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity.
Industry:Pharmaceutical
A cancer vaccine containing dendritic cells (DCs) that are transfected with messenger RNA (mRNA) encoding human telomerase reverse transcriptase (hTERT) and survivin in addition to patient-specific melanoma-derived mRNA with potential immunostimulatory and antineoplastic activities. Upon administration, hTERT/survivin/melanoma tumor cell-derived mRNA-transfected dendritic cell vaccine may elicit a highly specific cytotoxic T-cell (CTL) response against melanoma cells expressing hTERT, survivin, and patient-specific melanoma-associated antigens. HTERT, the catalytic subunit of human telomerase, and survivin, a member of the inhibitor of apoptosis (IAP) family of proteins, may be upregulated in certain tumor cell types, playing key roles in tumor cell growth and survival.
Industry:Pharmaceutical
A cancer vaccine containing autologous dendritic cells electroporated with full-length mRNA encoding Wilms' tumor 1 (WT1) antigen with potential immunostimulatory and antineoplastic activities. Upon administration, WT1 mRNA-electroporated autologous dendritic cell vaccine may elicit a cytotoxic T-cell (CTL) response against tumor cells expressing WT1. Wt1 is frequently overexpressed in a variety of tumor cell types and often correlates with disease progression and poor prognosis.
Industry:Pharmaceutical
A cancer vaccine containing an HLA-A*0201-restricted vascular endothelial growth factor receptor 1 (VEGFR1) peptide (sequence: TLFWLLLTL) with potential immunostimulatory and antitumor activities. Upon administration, HLA-A*0201-restricted VEGFR1-derived peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing VEGFR1, resulting in tumor cell lysis and decreased tumor growth. HLA-A*0201 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*0201 may improve antigenic peptide immunogenicity.
Industry:Pharmaceutical
A cancer vaccine containing a replication-defective recombinant canarypox virus (ALVAC), encoding an epitope of MART-1 (melanoma antigen recognized by T-cells), with potential immunostimulatory and antineoplastic activities. Upon administration, the MART-1 epitope is expressed by the ALVAC vector in ALVAC-MART-1 vaccine; a host cytotoxic T lymphocyte (CTL) response against MART-1-expressing tumor cells may follow, resulting in tumor cell lysis and decreased tumor cell proliferation.
Industry:Pharmaceutical
A cancer vaccine containing a RAS oncogene-encoded peptide with potential antineoplastic activity. RAS peptide cancer vaccine may stimulate a RAS peptide-specific antitumoral T-cell cytotoxic immune response, resulting in an inhibition of tumor cell proliferation and tumor cell death.
Industry:Pharmaceutical
A cancer vaccine containing a plasmid encoding the mammaglobin-A gene with potential immunostimulating and antineoplastic activities. Upon administration, mammaglobin-A DNA vaccine may induce both humoral and cytotoxic T lymphocyte (CTL) immune responses against tumor cells that express mammaglobin-A, which may result in decreased tumor growth. The 10 kiloDalton (kD) glycoprotein mammglobin-A is expressed in over 80% of human breast cancers.
Industry:Pharmaceutical
A cancer vaccine containing a mixture of killed bacteria with potential immunostimulatory and antineoplastic activities. Mixed bacteria vaccine (MBV or Coley’s toxins) consists of a pyrogenic bacterial lysate derived from Serratia marcescens and Streptococcus pyogenes; the active components in the lysate may be lipopolysaccharide (LPS), a component of the Gram-negative bacterial cell wall of Serratia, and streptokinase, an enzyme produced by Streptococcus pyogenes. LPS has been shown to stimulate the host humoral immune response and induce the release of various antitumor cytokines such as tumor necrosis factor (TNF) and interleukin-12 (IL-12).
Industry:Pharmaceutical
